Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed EBITDA Margin for 4 consecutive years, with 89.73% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin rose 358278.0% to 89.73% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 286.05% through Sep 2025, up 492072.0% year-over-year, with the annual reading at 6991.12% for FY2011, 504087.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 89.73% at Lexicon Pharmaceuticals, down from 11.13% in the prior quarter.
  • The five-year high for EBITDA Margin was 11.13% in Q2 2025, with the low at 3672.51% in Q3 2024.